Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shawn Flanagan

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Antimicrobial Agents and Chemotherapy|August 16, 2021
Population Pharmacokinetics of Rezafungin in Patients with Fungal InfectionsChristopher M Rubino, Shawn Flanagan
Diagnostic Microbiology and Infectious Disease|December 27, 2017
Determination of Tedizolid susceptibility interpretive criteria for gram-positive pathogens according to clinical and laboratory standards institute guidelinesMekki Bensaci, Shawn Flanagan, Taylor Sandison
Sports Health|September 28, 2012
Recovery from injury in sport: considerations in the transition from medical care to performance careWilliam Kraemer, Craig Denegar, Shawn Flanagan
Cureus|July 17, 2023
Urgency in the Treatment of Sudden Sensorineural Hearing LossThomas Kepler, Shawn Flanagan, Carl Hoegerl
Journal of Clinical Medicine|June 15, 2018
Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy VolunteersShawn Flanagan, Sonia L Minassian, Philippe Prokocimer
International Journal of Antimicrobial Agents|June 26, 2016
Effects of therapeutic and supratherapeutic doses of oral tedizolid phosphate on cardiac repolarisation in healthy volunteers: a randomised controlled studyShawn Flanagan, Jeffrey Litwin, Edward Fang, et al.
Microbiology Spectrum|May 8, 2023
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of InvestigationsShawn Flanagan, Helen Walker, Voon Ong, et al.
Antimicrobial Agents and Chemotherapy|November 28, 2023
Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasisStefan Roepcke, Julie Passarell, Helen Walker, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 DataElizabeth A Lakota, Voon Ong, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2021
Metabolism, Excretion, and Mass Balance of [<sup>14</sup>C]-Rezafungin in Animals and HumansVoon Ong, Sarah Wills, Deborah Watson, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Antimicrobial Agents and Chemotherapy|August 16, 2021
Population Pharmacokinetics of Rezafungin in Patients with Fungal InfectionsChristopher M Rubino, Shawn Flanagan
Diagnostic Microbiology and Infectious Disease|December 27, 2017
Determination of Tedizolid susceptibility interpretive criteria for gram-positive pathogens according to clinical and laboratory standards institute guidelinesMekki Bensaci, Shawn Flanagan, Taylor Sandison
Sports Health|September 28, 2012
Recovery from injury in sport: considerations in the transition from medical care to performance careWilliam Kraemer, Craig Denegar, Shawn Flanagan
Cureus|July 17, 2023
Urgency in the Treatment of Sudden Sensorineural Hearing LossThomas Kepler, Shawn Flanagan, Carl Hoegerl
Journal of Clinical Medicine|June 15, 2018
Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy VolunteersShawn Flanagan, Sonia L Minassian, Philippe Prokocimer
International Journal of Antimicrobial Agents|June 26, 2016
Effects of therapeutic and supratherapeutic doses of oral tedizolid phosphate on cardiac repolarisation in healthy volunteers: a randomised controlled studyShawn Flanagan, Jeffrey Litwin, Edward Fang, et al.
Microbiology Spectrum|May 8, 2023
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of InvestigationsShawn Flanagan, Helen Walker, Voon Ong, et al.
Antimicrobial Agents and Chemotherapy|November 28, 2023
Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasisStefan Roepcke, Julie Passarell, Helen Walker, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 DataElizabeth A Lakota, Voon Ong, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2021
Metabolism, Excretion, and Mass Balance of [<sup>14</sup>C]-Rezafungin in Animals and HumansVoon Ong, Sarah Wills, Deborah Watson, et al.
Pageof 3